Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Thu, Jan 2, 2025
[Archive]
Volume 14, Issue 4 (Autumn 2023)
Caspian J Intern Med 2023, 14(4): 687-693 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Valizadeh Toosi S M, Hosseini V, Shokri-Afra H, Maleki I. Non-inferiority of reverse hybrid regimen compared to standard concomitant regimen for H. pylori eradication in a randomized controlled trial. Caspian J Intern Med 2023; 14 (4) :687-693
URL: http://caspjim.com/article-1-3550-en.html
URL: http://caspjim.com/article-1-3550-en.html
Non-communicable Diseases Institute, Gut and Liver Research Center, Imam Khomeini Hospital, Sari, Iran , IMaleki@mazums.ac.ir
Abstract: (1048 Views)
Background: Helicobacter pylori (H. pylori) infection is strongly related to peptic ulcer disease, chronic gastritis, and gastric malignancies. Therefore, H. pylori eradication is necessary in these cases. This study was aimed to compare the efficacy of 14-day reverse hybrid therapy with standard 14-day concomitant regimen for H. pylori eradication in Iran.
Methods: Of the 317 patients with dyspepsia and H. pylori infection enrolled in the study, 153 and 164 patients were randomly assigned to reverse hybrid and concomitant groups, respectively. The reverse hybrid regimen containing pantoprazole, amoxicillin, clarithromycin, and metronidazole was taken every 12 hours in the first 7 days, however, Clarithromycin and Metronidazole were discontinued within the next 7 days. Patients in the concomitant group also received the same drugs for 14-day. Eradication confirmation tests were used 8 weeks after the end of treatments.
Results: A crowd of 281 patients continued the trial until the end. H. pylori eradication rates based on intention to treat analysis were 71.2% (109/153) and 83.5% (137/164) in reverse hybrid and concomitant groups, respectively (P = 0.007). By the per-protocol analysis, rates of eradication were 85.8% (109/127) and 89% (137/154), respectively (P = 0.428). Severe side effects were few in both groups. More side effects were observed in concomitant group (p < 0.001), however, the severity of side effects was not statistically different between the two regimens (P = 0.314). Reverse hybrid regimen was better tolerated (98% vs. 91.5%, P= 0.009).
Conclusion: Both 14-day reverse hybrid and concomitant regimens have a fair response rate in Iran.
Methods: Of the 317 patients with dyspepsia and H. pylori infection enrolled in the study, 153 and 164 patients were randomly assigned to reverse hybrid and concomitant groups, respectively. The reverse hybrid regimen containing pantoprazole, amoxicillin, clarithromycin, and metronidazole was taken every 12 hours in the first 7 days, however, Clarithromycin and Metronidazole were discontinued within the next 7 days. Patients in the concomitant group also received the same drugs for 14-day. Eradication confirmation tests were used 8 weeks after the end of treatments.
Results: A crowd of 281 patients continued the trial until the end. H. pylori eradication rates based on intention to treat analysis were 71.2% (109/153) and 83.5% (137/164) in reverse hybrid and concomitant groups, respectively (P = 0.007). By the per-protocol analysis, rates of eradication were 85.8% (109/127) and 89% (137/154), respectively (P = 0.428). Severe side effects were few in both groups. More side effects were observed in concomitant group (p < 0.001), however, the severity of side effects was not statistically different between the two regimens (P = 0.314). Reverse hybrid regimen was better tolerated (98% vs. 91.5%, P= 0.009).
Conclusion: Both 14-day reverse hybrid and concomitant regimens have a fair response rate in Iran.
Keywords: Concomitant, Eradication regimens, Helicobacter pylori infection, Reverse hybrid, Randomized controlled trial
Type of Study: Original Article |
Subject:
Gastroentrology
Received: 2022/07/2 | Accepted: 2022/09/13 | Published: 2023/09/28
Received: 2022/07/2 | Accepted: 2022/09/13 | Published: 2023/09/28
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
